AUTL
Autolus Therapeutics plcNASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
2.08
P/S
4.91
EV/EBITDA
-2.47
DCF Value
$-28.20
FCF Yield
-83.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
-27.8%
Operating Margin
-358.9%
Net Margin
-381.4%
ROE
-99.0%
ROA
-48.8%
ROIC
-51.0%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $24.3M | $-90.2M | $-0.34 |
| FY 2025 | $75.6M | $-287.5M | $-1.08 |
| Q3 2025 | $21.2M | $-79.1M | $-0.30 |
| Q2 2025 | $20.9M | $-47.9M | $-0.18 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
GB
Exchange
NASDAQ
Beta
1.94
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.